General proliferating cells

General proliferating cells refers to a physiological state where cells are actively progressing through the cell cycle (G1, S, G2, and M phases) to achieve division (Cooper, 2000, The Cell: A Molecular Approach). While not a single molecular entity, this state is the primary focus of traditional cytotoxic chemotherapy, which targets the machinery of cell division to treat malignancies (NCI, 2023). Drugs such as antimetabolites, alkylating agents, and microtubule inhibitors interact with various molecular components within these cells to induce cell cycle arrest or apoptosis (StatPearls, 2023). Because these agents lack specificity for cancerous cells, they also impact healthy tissues with high turnover rates, such as the hematopoietic system and intestinal epithelium, leading to significant clinical toxicities (Pardee & Stein, 2009, The Biology of the Cell Cycle). Consequently, general proliferating cells represents a broad therapeutic category rather than a discrete, druggable receptor or enzyme. Biomarkers such as Ki-67 and PCNA are frequently employed in clinical pathology to assess the proliferative index of tumors, which often correlates with disease aggressiveness and response to cycle-specific agents (Scholzen & Gerdes, 2000, J. Cell. Physiol.).

Other names

Rapidly dividing cellsCycling cellsMitotic cellsHyperproliferative cells

Cytotoxic agents targeting general proliferating cells typically act by inhibiting DNA synthesis (antimetabolites), causing DNA cross-linking (alkylating agents), or disrupting microtubule assembly/disassembly (taxanes and vinca alkaloids), thereby inducing cell cycle arrest and apoptosis (NCI, 2023; StatPearls, 2023).